Monthly prospective analysis of hematopoietic chimerism after allogeneic hematopoietic cell transplantation.

Abstract:

SUMMARY:Hematopoietic chimerism (HpC) was assayed monthly using a sensitive, polymerase chain reaction (PCR) -based method in consecutive patients. Between January 1998 and April 2002, 181 patients underwent non-T cell depleted allogeneic hematopoietic cell transplantation (HCT). A total of 163 patients were evaluable for HpC at 1 month (11 early deaths; no informative band for HpC analysis/no genomic DNA in seven). In all, 53 of 163 patients (33%, median recipient DNA of 15% (range 5-95)), 39 of 151 patients (26%), and 27 of 142 patients (19%) showed mixed chimerism (MC) at 1, 2, and 3 months after HCT, respectively. Conditioning regimen (busulfan-fludarabine-ATG vs BuCy, relative risk 3.99 (95% CI 1.16-10.92)), neutrophil engraftment (>/=day 17 vs /=5% recipient DNA at 1 month. Five patients experienced secondary graft failure. All five patients showed MC at 1 month with median recipient DNA of 40%. None of the 109 patients with complete chimerism experienced graft failure (P=0.002). Our study showed that MC shown on monthly analysis of HpC after allogeneic HCT is a significant predictor of secondary graft failure. Bone Marrow Transplantation (2003) 32, 423-431. doi:10.1038/sj.bmt.1704147

journal_name

Bone Marrow Transplant

authors

Lee KH,Lee JH,Choi SJ,Lee JH,Kim S,Seol M,Lee YS,Kim WK,Kwon MR,Choi SJ,Park CJ,Chi HS,Lee JS

doi

10.1038/sj.bmt.1704147

subject

Has Abstract

pub_date

2003-08-01 00:00:00

pages

423-31

issue

4

eissn

0268-3369

issn

1476-5365

pii

1704147

journal_volume

32

pub_type

杂志文章
  • Avoiding hepatic veno-occlusive disease: what do we know and where are we going?

    abstract::Hepatic venocclusive disease (VOD) is a common toxicity associated with myeloablative chemotherapy or chemoradiotherapy used to prepare patients for stem cell transplantation. A sizable proportion of patients who develop VOD die. It is clear that injury to endothelial cells and hepatocytes in zone 3 of the liver acinu...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,评审

    doi:10.1038/sj.bmt.1703014

    authors: Bearman SI

    更新日期:2001-06-01 00:00:00

  • Comparison of autologous peripheral blood stem cell dosing by ideal vs actual body weight.

    abstract::In this retrospective study, we evaluated the predictability of PBSC dose for hematopoietic engraftment comparing that calculated by ideal body weight (IBW) vs another calculated by actual body weight (ABW) for each patient. Sixty-three consecutive patients treated similarly using one transplant protocol were analyzed...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1701731

    authors: Waples JM,Moreb JS,Sugrue M,Belanger G,Kubilis P,Lynch JW,Gian V,Weeks F,Wingard J

    更新日期:1999-05-01 00:00:00

  • Therapy-induced Ph1 suppression in chronic myeloid leukemia: molecular and cytogenetic studies in patients treated with alpha-2b IFN, high-dose chemotherapy and autologous stem cell infusion.

    abstract::In this study, cytogenetic and molecular analyses were employed to assess the response to therapy in 29 chronic myeloid leukemia patients undergoing high dose chemotherapy followed by autologous stem cell infusion. Of these, 11 had previously achieved hematologic remission and cytogenetic improvement after alpha-2b in...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Lo Coco F,Mandelli F,Diverio D,Alimena G,De Fabritiis P,Meloni G,Cedrone M,Frontani M,Guerrasio A,Saglio G

    更新日期:1990-10-01 00:00:00

  • Peripheral blood stem cell for haploidentical transplantation with post-transplant high dose cyclophosphamide: detailed analysis of 181 consecutive patients.

    abstract::While bone marrow (BM) grafts were initially used for T-replete HLA-haploidentical related donors transplantation (Haplo-SCT) with post-transplantation cyclophosphamide (PT-Cy), the use of peripheral blood stem cell (PBSC) remains debated. We thus conducted a detailed analysis evaluating the incidence, risk factors, a...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,多中心研究

    doi:10.1038/s41409-019-0500-x

    authors: Granata A,Fürst S,Bramanti S,Legrand F,Sarina B,Harbi S,De Philippis C,Faucher C,Chabannon C,Lemarie C,Calmels B,Mariotti J,Maisano V,Weiller PJ,Mokart D,Vey N,Bouabdallah R,Castagna L,Blaise D,Devillier R

    更新日期:2019-11-01 00:00:00

  • Phase-2 trial of an intensified conditioning regimen for allogeneic hematopoietic cell transplant for poor-risk leukemia.

    abstract::Patients with poor-risk leukemia have a high relapse rate despite allogeneic transplant. We report on the phase-2 trial of an intensified allogeneic transplant regimen whose aim was tolerable toxicity and durable remission. Study patients (n=30) had unfavorable first remission cytogenetics, progression from myelodyspl...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2010.295

    authors: Stein AS,O'Donnell MR,Synold TW,Dagis AC,Tsirunyan A,Nademanee AP,Parker PM,Pullarkat VA,Snyder DS,Spielberger RT,Wong JY,Alvarnas JC,Thomas SH,Forman SJ

    更新日期:2011-09-01 00:00:00

  • Intestinal obstruction caused by bezoar: a rare complication after bone marrow transplantation.

    abstract::Gastrointestinal complications are described frequently after preparation of patients for bone marrow transplantation (BMT). Two patients who underwent BMT developed complications due to gastrointestinal bezoars. One patient developed intestinal obstruction, which necessitated emergency surgery, and the other patient ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Ben-Yehuda A,Ben-Yehuda-Salz D,Or R,Landau EH,Krausz MM

    更新日期:1989-01-01 00:00:00

  • Outcomes of second allogeneic hematopoietic stem cell transplantation for patients with acute lymphoblastic leukemia.

    abstract::For patients with ALL who relapse following allo-SCT, only a second SCT provides a realistic chance for long-term disease remission. We retrospectively analyzed the outcomes of 31 patients with relapsed ALL after a prior allo-SCT, who received a second SCT (SCT2) at our center. With a median follow-up of 3 years, 1- a...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2012.195

    authors: Poon LM,Bassett R Jr,Rondon G,Hamdi A,Qazilbash M,Hosing C,Jones RB,Shpall EJ,Popat UR,Nieto Y,Worth LL,Cooper L,De Lima M,Champlin RE,Kebriaei P

    更新日期:2013-05-01 00:00:00

  • Intravenous ribavirin therapy for adenovirus cystitis after allogeneic bone marrow transplantation.

    abstract::Acute hemorrhagic cystitis due to adenovirus infections may be more severe or protracted in immunocompromised patients. This patient with chronic graft-versus-host disease following allogeneic marrow transplantation for acute myelogenous leukemia developed painful hematuria due to adenovirus infection that failed to r...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Cassano WF

    更新日期:1991-03-01 00:00:00

  • Secondary myelodysplastic syndrome following bone marrow transplantation: report of two cases.

    abstract::We report two cases of secondary myelodysplastic syndrome (SMDS) which followed successful treatment of a primary malignancy with high-dose chemotherapy supported by reinfusion of autologous stem cells. The SMDS was diagnosed 24 months and 40 months, respectively, following autografting. Both patients lived for 7 mont...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Chan T,Juneja S,Wolf M,Januszewicz E,Cooper I

    更新日期:1994-02-01 00:00:00

  • HLA-mismatched hematopoietic SCT without in vitro T-cell depletion for myelodysplastic syndrome.

    abstract::Allogeneic hematopoietic SCT (HSCT) is currently the only curative treatment for myelodysplastic syndrome (MDS). However, many patients cannot find an HLA-matched donor. We have developed a new protocol for HLA-mismatched (including haploidentical) HSCT using G-CSF-primed BM plus G-CSF-mobilized PBSCs without in vitro...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章

    doi:10.1038/bmt.2009.351

    authors: Chen Y,Liu K,Xu L,Chen H,Liu D,Zhang X,Shi H,Han W,Wang Y,Zhao T,Wang J,Wang J,Huang X

    更新日期:2010-08-01 00:00:00

  • Hematopoietic stem cell transplantation for infantile osteopetrosis.

    abstract::Infantile osteopetrosis is a lethal disorder resulting from a severe defect in the ability of osteoclasts to resorb bone. The only therapy shown to be capable of providing lasting benefit is allogeneic hematopoietic stem cell transplantation (HCT). We report the outcome of 10 patients with infantile malignant osteopet...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1701474

    authors: Eapen M,Davies SM,Ramsay NK,Orchard PJ

    更新日期:1998-11-01 00:00:00

  • The clinical utility of CMV surveillance cultures and antigenemia following bone marrow transplantation.

    abstract::At our institution, the cytomegalovirus (CMV) prophylaxis protocol for allogeneic bone marrow transplant (BMT) recipients who are CMV-seropositive or receive marrow from a CMV-seropositive donor consists of a surveillance bronchoscopy approximately 35 days posttransplant. Patients with a positive surveillance bronchos...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章

    doi:10.1038/sj.bmt.1701525

    authors: Humar A,O'Rourke K,Lipton J,Messner H,Meharchand J,Mahony J,Walker I,Wasi P,McGeer A,Moussa G,Chua R,Mazzulli T

    更新日期:1999-01-01 00:00:00

  • Tacrolimus (FK506) and methotrexate regimens to prevent graft-versus-host disease after unrelated dog leukocyte antigen (DLA) nonidentical marrow transplantation.

    abstract::We previously reported an synergism between methotrexate and tacrolimus (FK506) in preventing graft-versus-host disease (GVHD) in dogs given DLA-nonidentical unrelated marrow grafts after 9.2 Gy of total body irradiation (TBI). Methotrexate was given at 0.4 mg/kg i.v. on days 1, 3, 6 and 11 and FK506 at 0.15 mg/kg/day...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Yu C,Storb R,Deeg HJ,Graham TC,Scheuning FG,Huss R,Seidel K,Fitzsimmons WE

    更新日期:1996-04-01 00:00:00

  • Multiple myeloma: the number of reinfused plasma cells does not influence outcome of patients treated with intensified chemotherapy and PBPC support.

    abstract::Multiple myeloma (MM) is characterized by the expansion of tumor plasma cells in bone marrow (BM), but neoplastic cells have been consistently detected in peripheral blood (PB). Peripheral blood progenitor cell (PBPC) collections have been widely used to support high-dose therapy for MM patients. A flow cytometric tec...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1702085

    authors: Boccadoro M,Omedé P,Dominietto A,Palumbo A,Bringhen S,Giaretta F,Ortolano B,Triolo S,Pileri A

    更新日期:2000-01-01 00:00:00

  • Hematopoietic cell transplantation for thalassemia and sickle cell disease: past, present and future.

    abstract::beta-Thalassemia major and sickle cell disease (SCD) are among the most common hereditary disorders worldwide. The supportive treatment of beta-thalassemia major requires chronic, life-long RBC transfusions, which cause progressive iron overload and the potential for impaired endocrine, cardiac and hepatic function. T...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,评审

    doi:10.1038/sj.bmt.1705943

    authors: Bhatia M,Walters MC

    更新日期:2008-01-01 00:00:00

  • Risk factors and prognosis of hepatic acute GvHD after allogeneic hematopoietic cell transplantation.

    abstract::Hepatic acute GvHD (aGvHD) is associated with high mortality owing to poor response to immunosuppressive therapy. The pathogenesis of hepatic aGvHD differs from that of other lesions, and specific risk factors related to pre-transplant liver conditions should be determined. We conducted a cohort study by using a Japan...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1038/bmt.2015.205

    authors: Arai Y,Kanda J,Nakasone H,Kondo T,Uchida N,Fukuda T,Ohashi K,Kaida K,Iwato K,Eto T,Kanda Y,Nakamae H,Nagamura-Inoue T,Morishima Y,Hirokawa M,Atsuta Y,Murata M,GVHD working group of the Japan Society for Hematopoietic Ce

    更新日期:2016-01-01 00:00:00

  • Granulomatous pneumonitis following bone marrow transplantation.

    abstract::We describe the rare occurrence of a granulomatous pneumonitis seen in a patient following allogeneic bone marrow transplantation. Interestingly sarcoidosis was diagnosed in the marrow donor less than a year after donating his bone marrow. ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1703192

    authors: Sundar KM,Carveth HJ,Gosselin MV,Beatty PG,Colby TV,Hoidal JR

    更新日期:2001-09-01 00:00:00

  • Improved immune recovery after transplantation of TCRαβ/CD19-depleted allografts from haploidentical donors in pediatric patients.

    abstract::Immune recovery was retrospectively analyzed in a cohort of 41 patients with acute leukemia, myelodysplastic syndrome and nonmalignant diseases, who received αβ T- and B-cell-depleted allografts from haploidentical family donors. Conditioning regimens consisted of fludarabine or clofarabine, thiotepa, melphalan and se...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2015.87

    authors: Lang P,Feuchtinger T,Teltschik HM,Schwinger W,Schlegel P,Pfeiffer M,Schumm M,Lang AM,Lang B,Schwarze CP,Ebinger M,Urban C,Handgretinger R

    更新日期:2015-06-01 00:00:00

  • Peripheral blood stem cell support does not accelerate haemopoietic recovery from miniBEAM chemotherapy.

    abstract::Intermediate-dose salvage therapy is frequently given for relapsed and resistant lymphomas and is usually intensely myelosuppressive. In an attempt to reduce the haematological toxicity of miniBEAM, one of the commonly used salvage regimens, peripheral blood stem cell (PBSC) support was given to 21 consecutive patient...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Fielding AK,Goldstone AH,Sullivan AM,Watts MJ,Jamieson E,Linch DC

    更新日期:1996-09-01 00:00:00

  • Extensive clonal expansion of T lymphocytes causes contracted diversity of complementarity-determining region 3 and skewed T cell receptor repertoires after allogeneic hematopoietic cell transplantation.

    abstract::We previously described skewed repertoires of the T cell receptor-beta chain variable region (TCRBV) and the TCR-alpha chain variable region (TCRAV) soon after allogeneic hematopoietic cell transplantation. To determine the characteristics of skewed TCRBV after transplantation, we examined the clonality of T lymphocyt...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1702858

    authors: Hirokawa M,Matsutani T,Horiuchi T,Kawabata Y,Kitabayashi A,Yoshioka T,Tsuruta Y,Suzuki R,Miura AB

    更新日期:2001-03-01 00:00:00

  • Rapid and massive expansion of cord blood-derived cytokine-induced killer cells: an innovative proposal for the treatment of leukemia relapse after cord blood transplantation.

    abstract::We have used a standardized 21-day expansion protocol to produce cytokine-induced killer (CIK) cells starting from very small amounts of nucleated cells (approximately 15 x 10(6) cells) isolated from cord blood. Mononuclear cells are stimulated with anti CD3 (OKT3) and IFNgamma and then expanded with IL-2. Moreover, w...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1705503

    authors: Introna M,Franceschetti M,Ciocca A,Borleri G,Conti E,Golay J,Rambaldi A

    更新日期:2006-11-01 00:00:00

  • Effect of granulocyte colony-stimulating factor on hematopoietic recovery after peripheral blood progenitor cell transplantation.

    abstract::To examine the effect of granulocyte colony-stimulating factor (G-CSF) on hematopoietic recovery after high-dose chemotherapy and peripheral blood progenitor cell transplantation (PBPCT), 20 patients with hematologic malignancies were divided into two groups. One group was given G-CSF at a daily dose of 50 micrograms/...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章

    doi:

    authors: Shimazaki C,Oku N,Uchiyama H,Yamagata N,Tatsumi T,Hirata T,Ashihara E,Okawa K,Goto H,Inaba T

    更新日期:1994-03-01 00:00:00

  • High-dose chemotherapy (HDCT) with auto-SCT in children with atypical teratoid/rhabdoid tumors (AT/RT): a report from the European Rhabdoid Registry (EU-RHAB).

    abstract::A retrospective analysis of data from the European Rhabdoid Registry (EU-RHAB) was performed to describe the outcome of children with atypical teratoid/rhabdoid tumors (AT/RT) who underwent high-dose chemotherapy (HDCT) with auto-SCT. Nineteen patients (male, n=15; median age at diagnosis 21 months) were identified. N...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2013.208

    authors: Benesch M,Bartelheim K,Fleischhack G,Gruhn B,Schlegel PG,Witt O,Stachel KD,Hauch H,Urban C,Quehenberger F,Massimino M,Pietsch T,Hasselblatt M,Giangaspero F,Kordes U,Schneppenheim R,Hauser P,Klingebiel T,Frühwald MC

    更新日期:2014-03-01 00:00:00

  • Pegfilgrastim vs filgrastim in PBSC mobilization for autologous hematopoietic SCT: a systematic review and meta-analysis.

    abstract::Trial outcomes comparing cytokine agents for PBSC mobilization in autologous hematopoietic transplant patients have been controversial. We performed a systematic review and meta-analysis of evidence available on pegfilgrastim vs filgrastim in chemo-cytokine mobilization. Electronic literature searches of PubMed, EMBAS...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,meta分析,评审

    doi:10.1038/bmt.2014.297

    authors: Kim MG,Han N,Lee EK,Kim T

    更新日期:2015-04-01 00:00:00

  • Veno-occlusive disease after high-dose busulfan-melphalan in neuroblastoma.

    abstract::Survival for high-risk neuroblastoma patients is still suboptimal. Although stem cell transplantation (SCT) is used, there is no consensus as to which conditioning regimen has the greatest efficacy and fewest toxicities. We assessed the incidence of and risk for hepatic veno-occlusive disease (VOD) for neuroblastoma p...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/s41409-018-0298-y

    authors: Schechter T,Perez-Albuerne E,Lin TF,Irwin MS,Essa M,Desai AV,Frangoul H,Yanik G,Dupuis LL,Jacobsohn D,Kletzel M,Ranalli M,Soni S,Seif AE,Grupp S,Dvorak CC

    更新日期:2020-03-01 00:00:00

  • Delayed engraftment and mixed chimerism after HLA-identical sibling donor BMT in Fanconi anaemia.

    abstract::A 12-year-old girl with Fanconi anaemia (FA) received a bone marrow transplant from her HLA-identical brother following conditioning with cyclophosphamide (20 mg/kg), thoraco-abdominal radiation (TAI) (4 Gy) and equine anti-thymocyte globulin (ATG) (90 mg/kg). Engraftment was delayed and initially tenuous, and was fol...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1701855

    authors: Mital MK,Curtis A,Spencer V,Barge D,Skinner R

    更新日期:1999-07-01 00:00:00

  • Multiple cycles of dose-intensive chemotherapy with repeated stem cell support as induction treatment in metastatic breast cancer: a feasibility study.

    abstract::The purpose of this trial was to study feasibility and tolerance of a dose-intensive multicyclic alternating induction chemotherapy with repeated stem cell support in a series of 43 metastatic breast cancer patients. Anthracycline-naive patients (n = 21) received cyclophosphamide 2.5 g/m(2) plus doxorubicin 80 mg/m(2)...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章

    doi:10.1038/sj.bmt.1703125

    authors: García-Rayo S,Pérez-Calvo J,Martín-Algarra S,Martínez-Monge R,Fernández-Hidalgo O,Subirá L,Martínez-Aguillo M,Rebollo J,Azinovic I,Brugarolas A

    更新日期:2001-08-01 00:00:00

  • Requirement for B cells in T cell priming to minor histocompatibility antigens and development of graft-versus-host disease.

    abstract::Increased understanding of minor histocompatibility complex (MiHC) antigen presentation to donor T cells may permit methods to modulate graft-versus-host disease (GVHD), a major complication of allogeneic bone marrow transplantation (BMT). Previously, we described the importance of B cells as antigen presenting cells ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Schultz KR,Paquet J,Bader S,HayGlass KT

    更新日期:1995-08-01 00:00:00

  • Evaluation of remission state in chronic myeloid leukemia patients after bone marrow transplantation using cytogenetic and molecular genetic approaches.

    abstract::The remission state of 13 Philadelphia positive chronic myeloid leukemia patients was studied after bone marrow transplantation (BMT) by cytogenetic and Southern blot analysis of the breakpoint cluster region (BCR) gene. Eight of 13 patients showed neither clinical nor genetic evidence of residual disease. In two pati...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Arnold R,Bartram CR,Heinze B,Carbonell F,Wiesneth M,Hertenstein B,Schmeiser T,Heit W,Kubanek B,Heimpel H

    更新日期:1989-07-01 00:00:00

  • Fludarabine induces growth arrest and apoptosis of cytokine- or alloantigen-stimulated peripheral blood mononuclear cells, and decreases production of Th1 cytokines via inhibition of nuclear factor kappaB.

    abstract::Fludarabine is a purine analog that has demonstrated significant activity in B-cell malignancies, including CLL. Fludarabine also possesses an immunosuppressive effect and is being used to prevent GVHD in hematopoietic stem cell transplantation. However, the molecular mechanism by which fludarabine inhibits immunoreac...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1705901

    authors: Nishioka C,Ikezoe T,Togitani K,Yokoyama A

    更新日期:2008-02-01 00:00:00